REGULATED PRESS RELEASE published on 05/23/2025 at 07:30, 1 year 4 months ago Vif succès de l’augmentation de capital de NFL Biosciences avec une levée plafonnée à 3 millions d’euros NFL Biosciences annonce une levée de fonds réussie de 3 millions d'euros pour financer son candidat médicament contre l'addiction au tabac. Allocation des fonds pour une étude de Phase 3 de NFL-101 NFL Biosciences NFL-101 Levée De Fonds Phase 3 Addiction Au Tabac
BRIEF published on 05/22/2025 at 17:50, 1 year 4 months ago NFL Biosciences Announces €2.2 Million Capital Increase NFL Biosciences Clinical Trials Capital Increase Biopharmaceuticals Investment Risks
BRIEF published on 05/22/2025 at 17:50, 1 year 4 months ago NFL Biosciences annonce une levée de fonds de 2,2 millions d'euros Augmentation De Capital NFL-101 Levée De Fonds Phase 3 Plateforme PrimaryBid
REGULATED PRESS RELEASE published on 05/22/2025 at 17:45, 1 year 4 months ago NFL Biosciences lance une levée de fonds d’environ 2,2 millions d’euros par voie d’augmentations de capital NFL Biosciences lance une levée de fonds de 2,2 millions d'euros pour étude sur le traitement des addictions avec nouveau médicament NFL-101 NFL Biosciences NFL-101 Levée De Fonds Addictions Étude Phase 3
REGULATED PRESS RELEASE published on 05/22/2025 at 17:45, 1 year 4 months ago NFL Biosciences launches a capital increase of approximately €2.2 million NFL Biosciences launches a €2.2 million capital increase through global offering for smoking cessation drug development. Subscription price: €1.20/share NFL Biosciences Capital Increase Smoking Cessation Subscription Price Global Offering
BRIEF published on 05/21/2025 at 17:50, 1 year 4 months ago Résultats de l'Assemblée Générale de NFL Biosciences NFL Biosciences Actionnaires Assemblée Générale Biopharmaceutique Resolutions
BRIEF published on 05/21/2025 at 17:50, 1 year 4 months ago NFL Biosciences General Meeting Results NFL Biosciences Shareholders Biopharmaceuticals Resolutions General Assembly
REGULATED PRESS RELEASE published on 05/21/2025 at 17:45, 1 year 4 months ago NFL Biosciences : compte rendu de l’assemblée générale mixte du 21 mai 2025 Compte rendu de l'assemblée générale mixte de NFL Biosciences du 21 mai 2025. Résolutions approuvées pour le développement de médicaments botaniques innovants pour traiter les addictions NFL Biosciences Médicaments Botaniques Assemblée Générale Mixte Résolutions Approuvées Addictions
BRIEF published on 05/12/2025 at 08:35, 1 year 4 months ago NFL Biosciences Restructures Scientific Committee for NFL-101 Advancement NFL Biosciences NFL-101 Phase 3 Trials Tobacco Addiction Scientific Committee
BRIEF published on 05/12/2025 at 08:35, 1 year 4 months ago NFL Biosciences renforce son Comité Scientifique pour le développement de NFL-101 NFL Biosciences NFL-101 Phase 3 Addiction Tabac Comité Scientifique
Published on 09/23/2026 at 15:42, 1 hour 18 minutes ago Global Atomic Announces C$50 Million Public Offering of Units
Published on 09/23/2026 at 14:31, 2 hours 29 minutes ago First Breach Completes First Untethered Flight of Proprietary Drone Prototype, Advancing American-Made Unmanned Systems Program
Published on 09/23/2026 at 14:30, 2 hours 30 minutes ago Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
Published on 09/23/2026 at 14:00, 3 hours ago Integrated Rewards Launches "Celebrate Canadian" Campaign to Connect Canadian Brands with Millions of Consumers
Published on 09/23/2026 at 13:30, 3 hours 30 minutes ago Engineering Cost Study Validates Commercial-Scale U.S. HPMSM Capital Cost and Establishes EMM Capital Cost for Electric Metals' North Star Manganese Project
Published on 09/23/2026 at 16:55, 4 minutes ago Bird.com secures $450m financing as it launches communications infrastructure for AI agents
Published on 09/23/2026 at 16:40, 19 minutes ago Xryma Plc Goes Live on the ECB T2 Real-Time Gross Settlement Network
Published on 09/23/2026 at 16:30, 29 minutes ago nobilia and Coohom Forge Strategic Global Partnership to Redefine the Future of Kitchen Planning with Spatial Intelligence
Published on 09/23/2026 at 15:42, 1 hour 17 minutes ago Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 09/23/2026 at 15:41, 1 hour 18 minutes ago Form 8.3 - The Vanguard Group, Inc.: Permanent TSB Group Holdings plc
Published on 09/23/2026 at 08:00, 9 hours ago Résultats semestriels 2026 - ANR par action : 101,90 €, en progression de 8,18 % - Capitaux propres consolidés : 774,5 M€
Published on 09/22/2026 at 18:00, 23 hours ago Consolidated results for the first half of 2026 EBITDA : 60,5 M€
Published on 09/22/2026 at 18:00, 23 hours ago Résultats consolidés du premier semestre 2026 EBITDA : 60,5 M€
Published on 09/22/2026 at 17:45, 23 hours 15 minutes ago Imerys-09-2026-information-share-capital-and-voting-rights-as-of-31-August-2026
